213 related articles for article (PubMed ID: 23110398)
1. Live attenuated influenza viruses produced in a suspension process with avian AGE1.CR.pIX cells.
Lohr V; Genzel Y; Jordan I; Katinger D; Mahr S; Sandig V; Reichl U
BMC Biotechnol; 2012 Oct; 12():79. PubMed ID: 23110398
[TBL] [Abstract][Full Text] [Related]
2. Influenza viruses production: Evaluation of a novel avian cell line DuckCelt®-T17.
Petiot E; Proust A; Traversier A; Durous L; Dappozze F; Gras M; Guillard C; Balloul JM; Rosa-Calatrava M
Vaccine; 2018 May; 36(22):3101-3111. PubMed ID: 28571695
[TBL] [Abstract][Full Text] [Related]
3. High cell density cultivations by alternating tangential flow (ATF) perfusion for influenza A virus production using suspension cells.
Genzel Y; Vogel T; Buck J; Behrendt I; Ramirez DV; Schiedner G; Jordan I; Reichl U
Vaccine; 2014 May; 32(24):2770-81. PubMed ID: 24583003
[TBL] [Abstract][Full Text] [Related]
4. Production of cell culture (MDCK) derived live attenuated influenza vaccine (LAIV) in a fully disposable platform process.
George M; Farooq M; Dang T; Cortes B; Liu J; Maranga L
Biotechnol Bioeng; 2010 Aug; 106(6):906-17. PubMed ID: 20589670
[TBL] [Abstract][Full Text] [Related]
5. Comparison of egg and high yielding MDCK cell-derived live attenuated influenza virus for commercial production of trivalent influenza vaccine: in vitro cell susceptibility and influenza virus replication kinetics in permissive and semi-permissive cells.
Hussain AI; Cordeiro M; Sevilla E; Liu J
Vaccine; 2010 May; 28(22):3848-55. PubMed ID: 20307595
[TBL] [Abstract][Full Text] [Related]
6. Continuous influenza virus production in a tubular bioreactor system provides stable titers and avoids the "von Magnus effect".
Tapia F; Wohlfarth D; Sandig V; Jordan I; Genzel Y; Reichl U
PLoS One; 2019; 14(11):e0224317. PubMed ID: 31689309
[TBL] [Abstract][Full Text] [Related]
7. High titer MVA and influenza A virus production using a hybrid fed-batch/perfusion strategy with an ATF system.
Vázquez-Ramírez D; Jordan I; Sandig V; Genzel Y; Reichl U
Appl Microbiol Biotechnol; 2019 Apr; 103(7):3025-3035. PubMed ID: 30796494
[TBL] [Abstract][Full Text] [Related]
8. Development of an efficient veterinary rabies vaccine production process in the avian suspension cell line AGE1.CR.pIX.
Trabelsi K; Zakour MB; Jordan I; Sandig V; Rourou S; Kallel H
BMC Biotechnol; 2022 Jun; 22(1):17. PubMed ID: 35715843
[TBL] [Abstract][Full Text] [Related]
9. Serum-free microcarrier based production of replication deficient influenza vaccine candidate virus lacking NS1 using Vero cells.
Chen A; Poh SL; Dietzsch C; Roethl E; Yan ML; Ng SK
BMC Biotechnol; 2011 Aug; 11():81. PubMed ID: 21835017
[TBL] [Abstract][Full Text] [Related]
10. Comparison of influenza virus yields and apoptosis-induction in an adherent and a suspension MDCK cell line.
Peschel B; Frentzel S; Laske T; Genzel Y; Reichl U
Vaccine; 2013 Nov; 31(48):5693-9. PubMed ID: 24113260
[TBL] [Abstract][Full Text] [Related]
11. Rationale for vaccination with trivalent or quadrivalent live attenuated influenza vaccines: Protective vaccine efficacy in the ferret model.
Rudenko L; Kiseleva I; Krutikova E; Stepanova E; Rekstin A; Donina S; Pisareva M; Grigorieva E; Kryshen K; Muzhikyan A; Makarova M; Sparrow EG; Torelli G; Kieny MP
PLoS One; 2018; 13(12):e0208028. PubMed ID: 30507951
[TBL] [Abstract][Full Text] [Related]
12. Production and antigenic properties of influenza virus from suspension MDCK-siat7e cells in a bench-scale bioreactor.
Chu C; Lugovtsev V; Lewis A; Betenbaugh M; Shiloach J
Vaccine; 2010 Oct; 28(44):7193-201. PubMed ID: 20800699
[TBL] [Abstract][Full Text] [Related]
13. Efficient influenza A virus production in high cell density using the novel porcine suspension cell line PBG.PK2.1.
Gränicher G; Coronel J; Pralow A; Marichal-Gallardo P; Wolff M; Rapp E; Karlas A; Sandig V; Genzel Y; Reichl U
Vaccine; 2019 Nov; 37(47):7019-7028. PubMed ID: 31005427
[TBL] [Abstract][Full Text] [Related]
14. Use of MDCK cells for production of live attenuated influenza vaccine.
Liu J; Shi X; Schwartz R; Kemble G
Vaccine; 2009 Oct; 27(46):6460-3. PubMed ID: 19559113
[TBL] [Abstract][Full Text] [Related]
15. [Selected problems of manufacturing influenza vaccines].
Augustynowicz E
Przegl Epidemiol; 2010; 64(3):373-80. PubMed ID: 20976949
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of replication, immunogenicity and protective efficacy of a live attenuated cold-adapted pandemic H1N1 influenza virus vaccine in non-human primates.
Boonnak K; Paskel M; Matsuoka Y; Vogel L; Subbarao K
Vaccine; 2012 Aug; 30(38):5603-10. PubMed ID: 22789506
[TBL] [Abstract][Full Text] [Related]
17. Alternative Strategy for a Quadrivalent Live Attenuated Influenza Virus Vaccine.
Wan Z; Cardenas Garcia S; Liu J; Santos J; Carnaccini S; Geiger G; Ferreri L; Rajao D; Perez DR
J Virol; 2018 Nov; 92(21):. PubMed ID: 30135124
[TBL] [Abstract][Full Text] [Related]
18. Serum-free influenza virus production avoiding washing steps and medium exchange in large-scale microcarrier culture.
Genzel Y; Fischer M; Reichl U
Vaccine; 2006 Apr; 24(16):3261-72. PubMed ID: 16472544
[TBL] [Abstract][Full Text] [Related]
19. Production of high-titer human influenza A virus with adherent and suspension MDCK cells cultured in a single-use hollow fiber bioreactor.
Tapia F; Vogel T; Genzel Y; Behrendt I; Hirschel M; Gangemi JD; Reichl U
Vaccine; 2014 Feb; 32(8):1003-11. PubMed ID: 24269322
[TBL] [Abstract][Full Text] [Related]
20. MDCK and Vero cells for influenza virus vaccine production: a one-to-one comparison up to lab-scale bioreactor cultivation.
Genzel Y; Dietzsch C; Rapp E; Schwarzer J; Reichl U
Appl Microbiol Biotechnol; 2010 Sep; 88(2):461-75. PubMed ID: 20617311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
